Moteur de recherche d’entreprises européennes
Financement de l’UE (3 664 174 €) : Alliance endothéliale macRophage dans la neuroinflammation Hor01/05/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Alliance endothéliale macRophage dans la neuroinflammation
Neurological diseases cause enormous suffering and a great economic burden. Almost 20 million Europeans are affected by the most frequently occurring and disabling disease entities, such as stroke, Alzheimer’s disease (AD), or multiple sclerosis (MS), and these numbers do not include the large group of rare diseases that affect the CNS. Overall, the annual costs for patient care amount to 400 billion Euros. Common features of many neurological diseases are a vascular pathology with impaired blood-brain barrier (BBB) function or with reduced blood flow and inflammatory changes. As the two are often associated, disentangling their intricate and mutual relationship is a major task for translational neuroscience that could improve the treatment of many neurological diseases. At the cellular level, key players are brain endothelial cells as the building blocks of cerebral vessels and macrophages as the main inflammatory cells of the brain. Recent discoveries indicate that endothelial cells and brain macrophages are in intimate contact and closely interact. However, there is a huge gap of knowledge regarding the specific mode and the consequences of these interactions. Therefore, in-depth analyses of the molecular mechanisms involved are essential to identify and understand key features of macrophage-endothelial cross-talk, and exploitation of this information for the development of treatments of neurological diseases. ENTRAIN will undertake this task, using novel and emerging technologies, such as cutting-edge chemoproteomics, unique genetic and viral tools for targeting of defined cell populations, and high resolution intravital imaging. By characterising the pas de deux of endothelial cells and macrophages at the functional and morphological level, we will lay the foundation for better therapies for neurological diseases. The results will impact on the understanding of neuroinflammation, but also on the rarefaction of vessels.
| BOEHRINGER INGELHEIM PHARMA GmbH & Co. KG | ? |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | 250 905 € |
| EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH | 281 277 € |
| HELSINGIN YLIOPISTO | 280 806 € |
| HUN-REN KISERLETI ORVOSTUDOMANYI KUTATOINTEZET | 229 715 € |
| Institut National de la Sante et de la Recherche Medicale | 274 802 € |
| Istituto Di Ricerche Farmacologiche Mario Negri | 261 500 € |
| MIMETAS B.V. | 265 620 € |
| STICHTING AMSTERDAM UMC | 265 620 € |
| Universita Degli Studi Di Brescia | 261 500 € |
| UNIVERSITAET BERN | 281 277 € |
| UNIVERSITAET MUENSTER | 252 788 € |
| UNIVERSITAETSKLINIKUM FREIBURG | 252 788 € |
| UNIVERSITAET zu LUEBECK | 505 577 € |
https://cordis.europa.eu/project/id/813294
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim a. Rhein, Allemagne.
